Researchers published a Nature Biotechnology paper detailing a generative‑model framework that enables petascale synthesis of designed DNA sequences for engineered biology and cell‑therapy candidates. The team demonstrated that manufacturing‑aware generative models can propose DNA designs at scale while accounting for synthesis constraints, lowering the barrier to producing large libraries and accelerating downstream cell therapy and synthetic biology workflows. The work bridges computational design and wet‑lab production, suggesting a path to scale up candidate generation and physical synthesis in parallel. The article highlights opportunities and cautions for integrating AI design with manufacturing validation.